Liver MR imaging with iron oxides: toward consensus and clinical practice
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Ferucarbotran and ferumoxide have been available on the market and under clinical investigation.
“Available on the market and under clinical investigation have been ferucarbotran (Resovist®) and ferumoxide (Feridex® (USA), Endorem® (EU); see Table 1 [146, 147].”
From Iron oxide nanoparticles: Diagnostic, therapeutic and theranostic applications (2019) · cites this paper as [146]
Especially SPION with a hydrodynamic diameter in the range of 50-150 nm show fast accumulation in the mononuclear phagocytic system.
“Especially SPION with a hydrodynamic diameter in the range of 50-150 nm show fast accumulation in the MPS, explaining why especially these iron oxide nanoparticles have been used for liver imaging purposes [146].”
From Iron oxide nanoparticles: Diagnostic, therapeutic and theranostic applications (2019) · cites this paper as [146]
Cited by
Sorted by citations
Iron oxide MR contrast agents for molecular and cellular imaging
Bulte, J. W. M., & Kraitchman, D. L. (2004) · NMR in Biomedicine · doi:10.1002/nbm.924 · Cited by 1,500 · see citing works
“Cellular imaging using iron oxides was first introduced for hepatic imaging.(43,44) Following intravenous injection, Figure 2.”
MethodIron oxide nanoparticles: Diagnostic, therapeutic and theranostic applications
Dadfar, S. M., Roemhild, K., Drude, N. I., von Stillfried, S., Knüchel, R., Kiessling, F., & Lammers, T. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.01.005 · Cited by 1,181 · see citing works
“cially these iron oxide nanoparticles have been used for liver imaging purposes [146].”
MethodSurface-Charge-Dependent Cell Localization and Cytotoxicity of Cerium Oxide Nanoparticles
Asati, A., Santra, S., Kaittanis, C., & Perez, J. M. (2010) · ACS Nano · doi:10.1021/nn100816s · Cited by 702 · see citing works
“Cytotoxicity experiments with the neutral dextran-coated iron oxide nanoparticles were not performed since it is well established that these nanoparticles are nontoxic.(27) 29”
Gupta, A. K., & Wells, S. (2004) · IEEE Transactions on NanoBioscience · doi:10.1109/tnb.2003.820277 · Cited by 635 · see citing works
Villaraza, A. J. L., Bumb, A., & Brechbiel, M. W. (2010) · Chemical Reviews · doi:10.1021/cr900232t · Cited by 629 · see citing works
Reimer, P., & Balzer, T. (2003) · European Radiology · doi:10.1007/s00330-002-1721-7 · Cited by 614 · see citing works
“A variety of parenterally administered iron oxides have been developed for contrast-enhanced MR imaging of the liver [3].”
BackgroundInfluentialLong-circulating iron oxides for MR imaging
Weissleder, R., Bogdanov, A. A., Jr., Neuwelt, E. A., & Papisov, M. I. (1995) · Advanced Drug Delivery Reviews · doi:10.1016/0169-409x(95)00033-4 · Cited by 399 · see citing works
Self-citationCell toxicity of superparamagnetic iron oxide nanoparticles
Mahmoudi, M., Simchi, A., Milani, A. S., & Stroeve, P. (2009) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2009.04.046 · Cited by 376 · see citing works
Modo, M., Hoehn, M., & Bulte, J. W. M. (2005) · Molecular Imaging · doi:10.1162/15353500200505145 · Cited by 296 · see citing works
“resident phagocytes of the liver, using iron oxides [19,20], provided the rationale to further develop this approach to visualize macrophages elsewhere in the body.”
BackgroundBiomedical nanoparticle carriers with combined thermal and magnetic responses
Liu, T., Hu, S., Liu, D., Chen, S., & Chen, I. (2008) · Nano Today · doi:10.1016/j.nantod.2008.10.011 · Cited by 273 · see citing works
Gadolinium-Based Hybrid Nanoparticles as a Positive MR Contrast Agent
Hifumi, H., Yamaoka, S., Tanimoto, A., Citterio, D., & Suzuki, K. A. O. (2006) · Journal of the American Chemical Society · doi:10.1021/ja066442d · Cited by 239 · see citing works
LaConte, L. E. W., Nitin, N., & Bao, G. (2005) · Materials Today · doi:10.1016/s1369-7021(05)00893-x · Cited by 230 · see citing works
Nanoparticles for Imaging: top or Flop?
Kiessling, F., Mertens, M. E., Grimm, J., & Lammers, T. (2014) · Radiology · doi:10.1148/radiol.14131520 · Cited by 228 · see citing works
Metallic nanoparticles: technology overview & drug delivery applications in oncology
Ahmad, M. Z., Akhter, S., Jain, G. K., Rahman, M., Pathan, S. A., Ahmad, F. J., & Khar, R. K. (2010) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2010.498473 · Cited by 216 · see citing works
“It was possible because normal liver cells take up SPIOs, which results in darkening of the image; however, cancerous cells are not able to take up the SPIOs, thus resulting in a bright spot in tumour cells [150-153].”
BackgroundTargeting of Hematopoietic Progenitor Cells with MR Contrast Agents
Daldrup-Link, H. E., Rudelius, M., Oostendorp, R. A. J., Settles, M., Piontek, G., Metz, S., Rosenbrock, H., Keller, U., Heinzmann, U., Rummeny, E. J., et al. (2003) · Radiology · doi:10.1148/radiol.2283020322 · Cited by 200 · see citing works
Lunov, O., Syrovets, T., Röcker, C., Tron, K., Nienhaus, G. U., Rasche, V., Mailänder, V., Landfester, K., & Simmet, T. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.08.003 · Cited by 192 · see citing works
Hepatic MRI with SPIO: detection and characterization of focal liver lesions
Reimer, P., & Tombach, B. (1998) · European Radiology · doi:10.1007/s003300050535 · Cited by 188 · see citing works
Preparation of Magnetically Labeled Cells for Cell Tracking by Magnetic Resonance Imaging
Bulte, J. W. M., Arbab, A. S., Douglas, T., & Frank, J. A. (2004) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(04)86013-0 · Cited by 175 · see citing works
Ten Things You Might Not Know about Iron Oxide Nanoparticles
Daldrup-Link, H. E. (2017) · Radiology · doi:10.1148/radiol.2017162759 · Cited by 176 · see citing works
Daldrup-Link, H. E., Meier, R., Rudelius, M., Piontek, G., Piert, M., Metz, S., Settles, M., Uherek, C., Wels, W. S., Schlegel, J., et al. (2004) · European Radiology · doi:10.1007/s00330-004-2526-7 · Cited by 167 · see citing works
“, the dextran coat is degraded and eliminated via the kidneys, whereas the iron oxides are distributed to the normal iron metabolism, such as heme synthesis or storage in the liver [29, 31].”
BackgroundTang, Y., Yamashita, Y., Arakawa, A., et al. (1999) · American Journal of Roentgenology · doi:10.2214/ajr.172.6.10350287 · Cited by 151 · see citing works
Allkemper, T., Bremer, C., Matuszewski, L., Ebert, W., & Reimer, P. (2002) · Radiology · doi:10.1148/radiol.2232010241 · Cited by 124 · see citing works
“However, iron oxide preparations such as AMI-25 and AMI-227 may not be bolus injectable because of cardiovascular side effects and lumbar pain, and MION-37 and MION-46 preparations have been tested in only animal models so far (8,43).”
BackgroundSuperparamagnetic FePt nanoparticles as excellent MRI contrast agents
Maenosono, S., Suzuki, T., & Saita, S. (2008) · Journal of Magnetism and Magnetic Materials · doi:10.1016/j.jmmm.2008.01.026 · Cited by 119 · see citing works
Imaging-guided precision hyperthermia with magnetic nanoparticles
Shakeri‐Zadeh, A., & Bulte, J. W. M. (2024) · Nature Reviews Bioengineering · doi:10.1038/s44222-024-00257-3 · Cited by 121 · see citing works
“Several SPIO nanoparticle formulations have entered clinical use, mostly as MRI contrast agents for visualizing the reticuloendothelial system, including the liver 116 and lymph nodes 21 .”
Daldrup-Link, H. E., Rummeny, E. J., Ihssen, B., et al. (2002) · European Radiology · doi:10.1007/s00330-001-1270-5 · Cited by 83 · see citing works
“Ferumoxides (Endorem®, Laboratoire Guerbet, Aulnay-sous-Bois, France) are colloid based superparamagnetic iron oxide particles with an R2/R1 relaxivity ratio (L×mmol–1 s–1) of 160/40 [18].”
BackgroundOberdick, S. D., Jordanova, K. V., Lundstrom, J. T., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-38222-6 · Cited by 80 · see citing works
Glial brain tumor targeting of magnetite nanoparticles in rats
Mykhaylyk, O. M., Черченко, А. П., Ilkin, A., Dudchenko, N. O., Ruditsa, V., Novoseletz, M., & Zozulya, Y. (2001) · Journal of Magnetism and Magnetic Materials · doi:10.1016/s0304-8853(00)01264-6 · Cited by 74 · see citing works
Bonk, R. T., Schmiedl, U. P., Yuan, C., Nelson, J. A., BLACK, C. D. V., & Ladd, D. L. (2000) · Journal of Magnetic Resonance Imaging · doi:10.1002/1522-2586(200006)11:6 · Cited by 10 · see citing works
LIVER-SPECIFIC MR IMAGING CONTRAST AGENTS
Hahn, P. F., & Saini, S. (1998) · Radiologic Clinics of North America · doi:10.1016/s0033-8389(05)70022-1 · Cited by 74 · see citing works
Mn2+-doped silica nanoparticles for hepatocyte-targeted detection of liver cancer in T1-weighted MRI
Kim, S. M., Im, G. H., Lee, D.-G., et al. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.08.009 · Cited by 64 · see citing works
Lutz, A. M., Willmann, J. K., Goepfert, K., Marinček, B., & Weishaupt, D. (2005) · Radiology · doi:10.1148/radiol.2372041183 · Cited by 63 · see citing works
Watanabe, R., Matsumura, M., Chen, C., et al. (2003) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.26.1272 · Cited by 60 · see citing works
Intracellular Endosomal Magnetic Labeling of Cells
Bulte, J. W. M. (2006) · Humana Press eBooks · doi:10.1385/1-59745-010-3:419 · Cited by 55 · see citing works
Kim, D., Hong, K. S., & Song, J. (2007) · Molecules and Cells · doi:10.1016/s1016-8478(23)07365-x · Cited by 52 · see citing works
Meier, R., Golovko, D. M., Tavri, S., Henning, T. D., Knopp, C., Piontek, G., Rudelius, M., Heinrich, P., Wels, W. S., & Daldrup-Link, H. E. (2010) · Magnetic Resonance in Medicine · doi:10.1002/mrm.22652 · Cited by 45 · see citing works
Chen, F., Ward, J., & Robinson, P. J. (1999) · Magnetic Resonance Imaging · doi:10.1016/s0730-725x(98)00193-3 · Cited by 44 · see citing works
Multicentre Dose-Ranging Study on the Efficacy of USPIO Ferumoxtran-10 for Liver MR Imaging
Saini, S., Sharma, R., BARON, R. L., Turner, D. A., Ros, P. R., Hahn, P. F., Small, W. C., DeLange, E. E., Stillman, A. E., Edelman, R. R., et al. (2000) · Clinical Radiology · doi:10.1053/crad.2000.0504 · Cited by 44 · see citing works
Ferumoxytol-Enhanced MRI in Children and Young Adults: State of the Art
Adams, L. C., Jayapal, P., Ramasamy, S. K., Morakote, W., Yeom, K. W., Baratto, L., & Daldrup-Link, H. E. (2022) · American Journal of Roentgenology · doi:10.2214/ajr.22.28453 · Cited by 44 · see citing works
van Etten, B., van der Sijp, J. R. M., Kruyt, R. H., et al. (2002) · European Journal of Surgical Oncology · doi:10.1053/ejso.2001.1251 · Cited by 39 · see citing works
Magnetic resonance and fluorescence based molecular imaging technologies
Sosnovik, D. E., & Weissleder, R. (2005) · Birkhäuser Basel eBooks · doi:10.1007/3-7643-7426-8_3 · Cited by 36 · see citing works
Self-citationSchima, W., Mukerjee, A. K., & Saini, S. (1996) · Clinical Radiology · doi:10.1016/s0009-9260(96)80339-4 · Cited by 35 · see citing works
Magnetic Nanoparticles as Contrast Agents for MR Imaging
Bulte, J. W. M., & Brooks, R. A. (1997) · Springer eBooks · doi:10.1007/978-1-4757-6482-6_40 · Cited by 34 · see citing works
Key factors in the acquisition of contrast kinetic data for oncology
Evelhoch, J. L. (1999) · Journal of Magnetic Resonance Imaging · doi:10.1002/(sici)1522-2586(199909)10:3 · Cited by 366 · see citing works
Initial assessment of magnetoferritin biokinetics and proton relaxation enhancement in rats
Bulte, J. W. M., Douglas, T., Mann, S., et al. (1995) · Academic Radiology · doi:10.1016/s1076-6332(05)80064-9 · Cited by 32 · see citing works
“The latter group of magnetic resonance (MR) contrast agents currently is being evaluated in clinical trials for contrast-enhanced imaging of the liver [6] and lymph nodes [7].”
BackgroundImaging Evaluation of Hepatocellular Carcinoma
Kamel, I. R., & Bluemke, D. A. (2002) · Journal of Vascular and Interventional Radiology · doi:10.1016/s1051-0443(07)61784-9 · Cited by 32 · see citing works
Lewis, K. H., & CHEZMAR, J. L. (1997) · Magnetic Resonance Imaging Clinics of North America · doi:10.1016/s1064-9689(21)00198-7 · Cited by 28 · see citing works
Vonken, E.-J. P. A., van Osch, M. J. P., Bakker, C. J. G., & Viergever, M. A. (1999) · Journal of Magnetic Resonance Imaging · doi:10.1002/(sici)1522-2586(199908)10:2 · Cited by 176 · see citing works
Nanotechnology in diagnosis and therapy of gastrointestinal cancer
Liang, M., Li, L.-D., Li, L., & Li, S. (2022) · World Journal of Clinical Cases · doi:10.12998/wjcc.v10.i16.5146 · Cited by 25 · see citing works
The effects of iron oxide incorporation on the chondrogenic potential of three human cell types
Saha, S., Yang, X., Tanner, S. F., Curran, S. J., Wood, D. J., & Kirkham, J. (2012) · Journal of Tissue Engineering and Regenerative Medicine · doi:10.1002/term.544 · Cited by 25 · see citing works
“ResovistW can be used to label HBMSCs or mature chondrocytes for MR imaging of cells for cartilage tissue engineering.”
MethodDupas, B., Berreur, M., Rohanizadeh, R., et al. (1999) · Biology of the Cell · doi:10.1016/s0248-4900(99)80042-2 · Cited by 24 · see citing works
“111, 1990; Weissleder et I~I, 1990; Weissleder, 1994).”
Evaluation of portal MR angiography using superparamagnetic iron oxide
Knollmann, F. D., Böck, J., Teltenkötter, S., et al. (1997) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.1880070129 · Cited by 23 · see citing works
“The use of superparamagnetic iron oxides is emerging as a safe and efficient way to improve detection of liver tumors by MRI (7-10).”
BackgroundTumor-tropic Trojan horses: Using mesenchymal stem cells as cellular nanotheranostics
Rosu, A., Ghaemi, B., Bulte, J. W. M., & Shakeri‐Zadeh, A. (2023) · Theranostics · doi:10.7150/thno.90187 · Cited by 21 · see citing works
“MRI is the only modality for which NPs have been clinically approved as imaging agents: superparamagnetic iron oxide (SPIO) NPs have been used for diagnosis of liver cancer [78] and lymph node metastases [79, 80].”
MethodSynergistic enhancement of iron oxide nanoparticle and gadolinium for dual-contrast MRI
Zhang, F., Huang, X., Qian, C., et al. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.07.168 · Cited by 21 · see citing works
“On the other hand, superparamagnetic iron oxide (SPIO) NPs with superior magnetic properties have emerged as a prevailing agent due to their strong T2 shortening effect [3,4].”
Magnetic Nanoparticle Assisted Molecular MR Imaging
Jun, Y., Jang, J.-T., & Cheon, J. (2007) · Advances in experimental medicine and biology · doi:10.1007/978-0-387-76713-0_7 · Cited by 21 · see citing works
Gansbeke, D. V., Metens, T., Matos, C., et al. (1997) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.1880070306 · Cited by 21 · see citing works
Automatic vessel segmentation using active contours in cine phase contrast flow measurements
Kozerke, S., Botnar, R. M., Oyre, S., Scheidegger, M. B., Pedersen, E. M., & Boesiger, P. (1999) · Journal of Magnetic Resonance Imaging · doi:10.1002/(sici)1522-2586(199907)10:1 · Cited by 98 · see citing works
Baio, G., Fabbi, M., de Totero, D., et al. (2006) · Magnetic Resonance Materials in Physics Biology and Medicine · doi:10.1007/s10334-006-0059-6 · Cited by 19 · see citing works
Contrast Agents in Abdominal Imaging
Schneider, G. K., Reimer, P., Mamann, A., Kirchin, M. A., Morana, G., & Grazioli, L. (2005) · Topics in Magnetic Resonance Imaging · doi:10.1097/01.rmr.0000189025.80743.5c · Cited by 19 · see citing works
Contrast Agents for Hepatic Magnetic Resonance Imaging
Morana, G., Grazioli, L., Testoni, M., et al. (2002) · Topics in Magnetic Resonance Imaging · doi:10.1097/00002142-200206000-00002 · Cited by 18 · see citing works
“, the differentiation of the bright signal intensity of small liver lesions from the bright signal intensity of blood vessels viewed in cross section may be a challenge on delayed SPIO-enhanced MR images (47).”
BackgroundScott, J. G., Ward, J., Guthrie, J. A., et al. (2000) · Magnetic Resonance Imaging · doi:10.1016/s0730-725x(00)00116-8 · Cited by 18 · see citing works
Hirohashi, S., Ueda, K., Uchida, H., et al. (2000) · Radiology · doi:10.1148/radiology.217.2.r00nv26415 · Cited by 16 · see citing works
Multidetector Row CT and MR Imaging in Diagnosing Hepatocellular Carcinoma
Murakami, T., Hori, M., Kim, T., et al. (2004) · Intervirology · doi:10.1159/000078474 · Cited by 15 · see citing works
Metallic nanoparticles in drug delivery and cancer treatment
Rahman, M., Alam, K., Hafeez, A., Ilyas, R., & Beg, S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-821095-6.00008-2 · Cited by 14 · see citing works
Contrast agents in magnetic resonance imaging
Dawson, P. (1996) · European Journal of Radiology · doi:10.1016/s0720-048x(96)01087-x · Cited by 14 · see citing works
Dynamic Contrast-Enhanced Magnetic Resonance Imaging in a Model of Splenic Metastasis
Runge, V. M., & Williams, N. M. (1998) · Investigative Radiology · doi:10.1097/00004424-199801000-00007 · Cited by 13 · see citing works
Stiskal, M., Schwickert, H. C., Demšar, F., et al. (1996) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.1880060205 · Cited by 13 · see citing works
“which produce positive hepatobiliary enhancement: 2) particulate agents extracted by the reticuloendothelial system (RES) of the liver represented by dextran-coated superparamagnetic iron oxides LAMI25 or polycrystalline iron oxide nanocompounds (PION)] (4,5); and 3) particulate agents coated with specific residues th…”
BackgroundSelf-citationBaker, S., & Перьянова, О. В. (2019) · SN Applied Sciences · doi:10.1007/s42452-019-0715-x · Cited by 12 · see citing works
The changing role of radiology in imaging liver tumors: an overview
Savcı, G. (1999) · European Journal of Radiology · doi:10.1016/s0720-048x(99)00113-8 · Cited by 10 · see citing works
“Today, MR seems to be the one-step test for both lesion detection and characterization [99].”
MethodBiodistribution and Pharmacokinetics of Nanoprobes
Kolishetti, N., Alexis, F., Pridgen, E. M., & Farokhzad, O. C. (2011) · doi:10.1002/9780470767047.ch4 · Cited by 9 · see citing works
Reimer, P., & Vosshenrich, R. (2004) · Der Radiologe · doi:10.1007/s00117-004-1026-8 · Cited by 8 · see citing works
Grandin, C. B. G., BEERS, B. E. V., Pauwels, S. A., et al. (1997) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.1880070117 · Cited by 8 · see citing works
“Ferumoxides particles are superparamagnetic iron oxide particles that are phagocytosed by the reticuloendothelial cells of liver and spleen (1).”
BackgroundGd-EOB-DTPA-Enhanced Magnetic Resonance Imaging Findings of Nondiffuse Fatty Change of the Liver
Yamamoto, A., Tamada, T., Sone, T., et al. (2010) · Journal of Computer Assisted Tomography · doi:10.1097/rct.0b013e3181ef1db1 · Cited by 7 · see citing works
Detection of Focal Hepatic Lesions
Jung, G., KRAHE, T., Kugel, H., et al. (1998) · Investigative Radiology · doi:10.1097/00004424-199802000-00001 · Cited by 7 · see citing works
MR contrast agents: Applications in hepatobiliary imaging
Cher, T., & Szklaruk, J. (2010) · Applied Radiology · doi:10.37549/ar1784 · Cited by 6 · see citing works
RCOM RADIOLOGICAL CASE OF THE MONTH
Kalva, S. P., Blake, M. A., & Sahani, D. V. (2006) · Applied Radiology · doi:10.37549/ar1396 · Cited by 6 · see citing works
MRI and Ultrasound Imaging of Nanoparticles for Medical Diagnosis
Perlman, O., & Azhari, H. (2018) · Springer eBooks · doi:10.1007/978-3-662-56333-5_8 · Cited by 6 · see citing works
Advances in imaging of colorectal cancer
Padhani, A. R. (1999) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(98)00048-1 · Cited by 6 · see citing works
SPIO-enhanced MR imaging of focal fatty liver lesions
Lwakatare, F., Yamashita, Y., Nakayama, M., et al. (2001) · Abdominal Imaging · doi:10.1007/s002610000128 · Cited by 5 · see citing works
SUPERPARAMAGNETIC IRON OXIDE‐ENHANCED MAGNETIC RESONANCE IMAGING OF THE LIVER IN BEAGLE DOGS
Chang, D., Kim, B., Yun, Y., et al. (2002) · Veterinary Radiology & Ultrasound · doi:10.1111/j.1740-8261.2002.tb00440.x · Cited by 5 · see citing works
Takahama, K., Amano, Y., Hayashi, H., et al. (2002) · Journal of Nippon Medical School · doi:10.1272/jnms.69.571 · Cited by 5 · see citing works
Magnetic resonance imaging: present position and future prospects
Curati, W. L., & Bydder, G. M. (1996) · European Journal of Cancer · doi:10.1016/0959-8049(96)00008-1 · Cited by 4 · see citing works
Enochs, W. S., Harsh, G. R., Hochberg, F. H., & Weissleder, R. (1999) · Journal of Magnetic Resonance Imaging · doi:10.1002/(sici)1522-2586(199902)9:2 · Cited by 247 · see citing works
Hammerstingl, R., Schwarz, W., Hochmuth, K., Staib-Sebler, E., Lorenz, M., & Vogl, T. J. (2001) · Der Radiologe · doi:10.1007/s001170050924 · Cited by 2 · see citing works
Theranostic Metallic Nanomedicine in Oncology: New Insights and Concerns
(2014) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9781608058846114030010 · Cited by 2 · see citing works
“However, the problem associated with EPR is the accumulation of nanoparticles in blood capillaries near the healthy cells which can be recognized by MPS [80].”
BackgroundSynthesis of Co–Organosilane–Au Nanocomposites via a Controlled Interphasic Reduction
Ojea‐Jiménez, I., Lorenzo, J., Rebled, J. M., et al. (2012) · Chemistry of Materials · doi:10.1021/cm300757j · Cited by 2 · see citing works
Magnetic Resonance Imaging of Hepatocellular Carcinoma
Vogl, T. J., & Hammerstingl, R. (1999) · Medical radiology · doi:10.1007/978-3-642-58641-5_7 · Cited by 2 · see citing works
Imaging Hepatocellular Carcinoma
Choon, H. T., Kuo, Y., & Blomley, M. J. K. (2003) · Cancer Reviews Asia-Pacific · doi:10.1142/s0219836303000335 · Cited by 2 · see citing works
Molekulare und parametrische Bildgebung mit Eisenoxiden
Matuszewski, L., Tombach, B., Heindel, W. L., & Bremer, C. (2007) · Der Radiologe · doi:10.1007/s00117-006-1451-y · Cited by 2 · see citing works
Early Diagnosis and Treatment of Gastrointestinal Cancer by Nanotechnology Applications
Naser, M., Nasr, M., & Shehata, L. H. (2023) · International Journal of Progressive Sciences and Technologies · doi:10.52155/ijpsat.v41.2.5784 · Cited by 1 · see citing works
Shaikh, S. (2022) · Springer eBooks · doi:10.1007/978-981-16-9535-3_11 · Cited by 1 · see citing works
Magnetic Resonance Nanoparticle Probes for Cancer Imaging
Jun, Y., Jang, J.-T., & Cheon, J. (2003) · Nanotechnologies for the Life Sciences · doi:10.1002/9783527610419.ntls0075 · Cited by 1 · see citing works
[Contrast media in magnetic resonance imaging of the liver].
Alexandre, M., Coffin, C., Caseiro‐Alves, F., et al. (1997) · PubMed
Magnetic Resonance Molecular Imaging Using Iron Oxide Nanoparticles
Zurkiya, O. (2006) · SMARTech Repository (Georgia Institute of Technology)
Application of Magnetic Colloids in Hydrogels for Tissue Engineering
Rivera-Llabres, V. G., Gentry, K., & Rinaldi, C. (2023) · Royal Society of Chemistry eBooks · doi:10.1039/bk9781839169755-00410
(2000) · Time to knit · doi:10.1016/s0246-0610(98)33380-0
New approaches for gadolinium-free radiological contrasts in magnetic resonance imaging
Bragança, J. D. S., Gois, J. F., Kanitz, C. L., et al. (2025) · Cuadernos de Educación y Desarrollo · doi:10.55905/cuadv17n1-112
Magnetic Nanocontrast Agents for Tracking Stem Cells and Chimeric Antibody Receptor T Cells
Mali, I., Chen, H. C., Mali, I., et al. (2025) · Royal Society of Chemistry eBooks · doi:10.1039/9781837676965-00139
Magnetresonanztomographie von Lebermetastasen — ein Überblick
Hammerstingl, R., Schwarz, W., & Vogl, T. J. (2002) · Springer eBooks · doi:10.1007/978-3-642-59385-7_9
Imaging Strategies for the Detection of Liver Lesions
Marchal, G. (2000) · Medical radiology · doi:10.1007/978-3-642-18194-8_1
- Authors
- Weissleder, R.
- Corresponding author
- Weissleder, R
- ORCID
- Weissleder, R
- Venue
- Radiology
- Published
- 1994-12
- Volume
- 193
- Issue
- 3
- Pages
- 593-595
- ISSN
- 0033-8419 (ISSN-L)
- 1527-1315
- OpenAlex
- W1997041883
- Cited by
- 101
- References
- 0
- Citations by year
- 2025: 2 · 2024: 1 · 2023: 4 · 2022: 3 · 2020: 1 · 2019: 2 · 2018: 1 · 2017: 1 · 2014: 2 · 2013: 1 · 2012: 3
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Radiology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Advanced MRI Techniques and Applications
- Health Sciences › Medicine › Epidemiology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Keywords
- liver MRI, iron oxide contrast agents, liver imaging, consensus recommendations, clinical practice
- MeSH terms
- Contrast Media, Dextrans, Humans, Iron, Liver, Liver Neoplasms, Magnetic Resonance Imaging, Oxides, Spleen, Clinical Trials, Phase II as Topic, Clinical Trials, Phase III as Topic, Ferrosoferric Oxide, Magnetite Nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
